This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
by Zacks Equity Research
Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
by Zacks Equity Research
Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out.
New Strong Sell Stocks for August 12th
by Zacks Equity Research
WKHS, SPCE, PASG, LYRA, and GO have been added to the Zacks Rank #5 (Strong Sell) List on August 12, 2021
Moving Average Crossover Alert: Passage Bio (PASG)
by Zacks Equity Research
Passage Bio (PASG) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Passage Bio (PASG) Looks Good: Stock Adds 5.4% in Session
by Zacks Equity Research
Passage Bio (PASG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio
by Zacks Equity Research
Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio
New Analyst Coverage Puts Spotlight on These 2 Stocks
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.